

Evaluation Form

General

Please fill in this form to receive your Certificate of Attendance (from Monday, June 24, 2019)!

Did the meeting provide the goals and learning outcomes formulated in the CME application by the organisers:

No ... rarely ... yes

Acquaintance with the most recent advances in **basic science** with regard to lymphoma

1 1 2 5 3 59 4 269 5 447

4.48

Learning of recent results of **translational research** in lymphoma

1 0 2 2 3 61 4 289 5 429

4.47

Information about the **most recent data from clinical studies**

1 2 2 0 3 25 4 174 5 580

4.7

General session

Please, provide your overall rating of the quality of the education offered at this meeting:

poor ... excellent NA
(Session Not Attended)

Plenary Session

1 1 2 4 3 19 4 208 5 498

NA 50 4.64

AACR-ICML joint Session	1 1 NA 308	2 3 4.5	3 25	4 174	5 269
Session 1: DLBCL: BIOLOGY	1 1 NA 215	2 0 4.51	3 36	4 199	5 330
Session 2: DLBCL: CLINICAL DATA	1 0 NA 59	2 0 4.64	3 18	4 224	5 480
Session 3: CLL	1 2 NA 147	2 2 4.62	3 25	4 175	5 430
Session 4: TREATMENT WITH NOVEL ANTIBODIES	1 0 NA 218	2 1 4.56	3 23	4 198	5 341
Session 5: T-Cell lymphoma	1 0 NA 168	2 2 4.55	3 26	4 220	5 365
Session 6: LYMPHOMA PATHOLOGY	1 1 NA 301	2 1 4.52	3 30	4 163	5 285
Session 7: HODGKIN LYMPHOMA	1 1 NA 100	2 2 4.65	3 21	4 186	5 471
Session 8: Follicular lymphoma	1 1 NA 125	2 3 4.58	3 30	4 204	5 418
Session 9: EXTRANODAL LYMPHOMAS	1 1 NA 208	2 1 4.55	3 24	4 201	5 346
UCLI-ICML joint session	1 2 NA 401	2 1 4.5	3 22	4 136	5 219
Session 10: ADVANCES IN CAR-T CELL TREATMENT	1 1 NA 155	2 2 4.61	3 31	4 171	5 421
Session 11: NEW DRUG COMBINATIONS	1 1 NA 217	2 2 4.6	3 25	4 167	5 369

Keynote lectures

Henry Kaplan Memorial
Lecture: C.H. June

1 0 2 3 3 23 4 167 5 486
NA 102 4.67

Gianni Bonadonna Memorial
Lecture: A.M. Melnick

1 0 2 4 3 37 4 179 5 422
NA 139 4.59

John Ultmann Memorial
Lecture: P. Gaulard

1 1 2 4 3 32 4 152 5 448
NA 144 4.64

Focus on... sessions

MANTLE CELL LYMPHOMA	1 0 NA 159	2 1 4.68	3 14	4 169	5 438
PET IMAGING	1 2 NA 319	2 2 4.5	3 31	4 152	5 273
PEDIATRIC LYMPHOMA	1 3 NA 557	2 1 4.48	3 19	4 62	5 138
RESULTS FROM SINGLE AGENT TRIALS	1 2 NA 402	2 1 4.47	3 24	4 141	5 209
ONGOING TRIALS	1 2 NA 328	2 1 4.46	3 28	4 177	5 243
CLL AND MORE	1 2 NA 241	2 0 4.6	3 21	4 164	5 352
CHEMOTHERAPY-FREE STRATEGIES	1 0 NA 231	2 0 4.56	3 24	4 192	5 332
NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS	1 1 NA 354	2 1 4.49	3 25	4 160	5 238
NON-CLINICAL NEW DRUGS	1 1 NA 390	2 3 4.47	3 26	4 143	5 216
HIGH RISK LARGE B-CELL LYMPHOMAS	1 0 NA 139	2 0 4.68	3 13	4 180	5 447
INDOLENT NON-FOLLICULAR LYMPHOMA	1 2 NA 160	2 1 4.61	3 20	4 192	5 405

Radiotherapy program

New guidelines from the international lymphoma radiation oncology group - ILROG
 1 5 2 1 3 22 4 124 5 166
 NA 461 4.4

Contemporary lymphoma treatment: radiation therapy issues
 1 7 2 1 3 20 4 100 5 172
 NA 479 4.43

Educational sessions

Meet the professor:#PCNSL, A CURABLE DISEASE
 1 1 2 1 3 16 4 110 5 288
 NA 363 4.64

Meet the professor:#DOUBLE HIT LYMPHOMA, SO WHAT?
 1 0 2 2 3 10 4 134 5 461
 NA 173 4.74

Meet the professor:#BREAST IMPLANT ASSOCIATED ALCL AND OTHER RARE T-CELL LYMPHOMAS
 1 0 2 1 3 24 4 107 5 242
 NA 405 4.58

Meet the professor: #NEW TREATMENT OPTIONS IN HAIRY CELL LEUKEMIA WITH FOCUS ON BRAF INHIBITORS
 1 3 2 0 3 13 4 91 5 177
 NA 495 4.55

Meet the professor:#HOW TO APPROACH CLL IN CLINICAL PRACTICE
 1 1 2 0 3 15 4 121 5 350
 NA 293 4.68

Meet the professor:#CUTANEOUS LYMPHOMAS
 1 0 2 2 3 19 4 95 5 279
 NA 384 4.65

Meet the professor:#MANAGING THE TOXICITIES OF CAR T-CELL THERAPY
 1 1 2 0 3 19 4 120 5 246
 NA 393 4.58

Meet the professor:#RARE B CELL LYMPHOMAS IN CHILDREN AND ADOLESCENTS
 1 2 2 0 3 10 4 66 5 143
 NA 558 4.57

Meet the professor:#MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?
 1 2 2 1 3 14 4 87 5 318
 NA 358 4.7

Meet the professor:#THE MODERN APPROACH TO
 1 0 2 0 3 12 4 125 5 393

MODERN APPROACH TO MANTLE CELL LYMPHOMA

NA 250 4.72

Meet the professor:#LIQUID BIOPSY: A CLINICAL TOOL, ALREADY?

1 4 2 2 3 29 4 117 5 246
NA 381 4.51

Meet the professor:#WHAT WE SHOULD KNOW ABOUT NK/T-CELL LYMPHOMAS

1 1 2 1 3 17 4 112 5 229
NA 419 4.58

TREATING HODGKIN LYMPHOMA IN THE NEW MILLENNIUM# OPTIONS FOR FIRST LINE THERAPY OF HODGKIN LYMPHOMA

1 1 2 1 3 19 4 168 5 381
NA 210 4.63

TREATING HODGKIN LYMPHOMA IN THE NEW MILLENNIUM# RELAPSED AND REFRACTORY DISEASE

1 1 2 1 3 19 4 167 5 366
NA 226 4.62

TREATING HODGKIN LYMPHOMA IN THE NEW MILLENNIUM# TREATMENT OF ELDERLY HODGKIN LYMPHOMA PATIENTS

1 2 2 11 3 37 4 134 5 351
NA 245 4.53

NEW DRUGS FOR NON-HODGKIN LYMPHOMA: BEYOND CHEMOTHERAPY#T CELL THERAPY: FULL SPEED AHEAD

1 1 2 2 3 14 4 157 5 291
NA 315 4.58

NEW DRUGS FOR NON-HODGKIN LYMPHOMA: BEYOND CHEMOTHERAPY#NEW DRUGS FOR OLD TARGETS

1 2 2 1 3 19 4 150 5 309
NA 299 4.59

NEW DRUGS FOR NON-HODGKIN LYMPHOMA: BEYOND CHEMOTHERAPY#NEW DRUGS FOR NEW TARGETS

1 3 2 1 3 22 4 150 5 307
NA 297 4.57

ESO - ESMIT Educational session

1 0 2 0 3 12 4 101 5 202
NA 464 4.6

Clinical Case Discussion sessions

DLBCL	1 0	2 1	3 15	4 141	5 445	
	NA 178	4.71				
HODGKIN LYMPHOMA	1 2	2 1	3 20	4 127	5 337	
	NA 293	4.63				
RADIOTHERAPY FOR LYMPHOMAS	1 3	2 2	3 14	4 96	5 188	
	NA 476	4.53				
DIFFICULT PATHOLOGICAL CASES	1 1	2 1	3 12	4 95	5 215	
	NA 455	4.61				
Case discussion: FL/INDOLENT LYMPHOMA	1 11	2 17	3 34	4 156	5 331	
	NA 231	4.42				
Case discussion: CLL	1 3	2 0	3 18	4 103	5 285	
	NA 371	4.63				
Case discussion: PTCL	1 1	2 4	3 23	4 103	5 250	
	NA 399	4.57				

ORGANISATION

	No	...	nearly	...	yes	
How would you rate the facilities and venue for the purposes of this meeting?	1 0	2 0	3 150	4 314	5 317	
	4.21					
How would you rate the management and organisation of this meeting?	1 0	2 0	3 131	4 309	5 341	
	4.27					

Personal Information

You are:

Hematologist 🖱️ 572

Oncologist 🖱️ 138

Radiotherapist 🖱️ 17

Other 🖱️ 94

Your main interest is:

Basic/translational
research 🖱️ 112

linical research 🖱️ 238

CLL, clinical 🖱️ 267

Lymphoma, clinical 🖱️
690

Myeloma, clinical 🖱️ 238

Other 🖱️ 26

How did you learn about 15-ICML?

Save-the-Date flyer /
Preliminary Program 🖱️
336

Call for abstract e-mail
🖱️ 90

Webpage
www.lymphcon.ch 🖱️
173

Colleague or
pharmaceutical
representative 🖱️ 354